ABSTRACT
OBJECTIVE: To explore the clinical application of screening cell combination method in the prediction of red blood cell alloantibody, so as to provide basis for clinical diagnosis. METHODS: From October 2018 to April 2020, 9 680 samples were screened with automatic blood group instrument, 79 patients with positive alloantibodies were identified by 4 sets of screening cells from different manufacturers (referred to as combined method). At the same time, cell panel Panocell-16 was used for comparative analysis. Meanwhile, the combined method was also used to identify the antibodies of 20 samples from National Center for Clinical Laboratories external quality assessment (EQA) in China and 12 samples from WHO EQA. RESULTS: The 79 alloantibodies included anti-Mia antibody (7 cases), anti-M antibody (13 cases), anti-Lea antibody (9 cases), anti-P1 antibody (2 cases), anti-E antibody (22 cases), anti-c + E antibody (9 cases), anti-D antibody (4 cases), anti-e antibody (2 cases), anti-C + e antibody (3 cases), anti-C antibody (3 cases), anti-H antibody (1 case), anti-Fyb antibody (1 case), anti-E + M antibody (1 case), autoantibody + anti-E (2 cases). However, 7 cases of anti-Mia antibody and 1 case of anti- Lea antibody were missed in Panocell-16 identification results. The results of antibody identification in 20 samples from National Center for Clinical Laboratories EQA in China and 12 samples from WHO EQA were 100% accurate by combination method. The identification results between combined method identification and Panocell-16 identification showed no significant difference. CONCLUSION: The combined method can identify the alloantibodies of red blood cells in Chinese population. The screening cells can be used for screening of irregular antibodies without wasting reagents at the same time.
